NeoGenomics (NASDAQ:NEO) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

NeoGenomics (NASDAQ:NEO) announced its quarterly earnings data on Wednesday. The medical research company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01, FiscalAI reports. The company had revenue of $209.25 million for the quarter, compared to analysts’ expectations of $206.70 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%. NeoGenomics’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period last year, the firm posted $0.03 EPS.

Here are the key takeaways from NeoGenomics’ conference call:

• Strong third-quarter performance led management to raise 2026 guidance: revenue is now expected at $807–$809 million and adjusted EBITDA at approximately $60 million. Total revenue grew 11% year over year to $209 million, while adjusted EBITDA increased 53% to $18.7 million.
• NGS remained the primary growth engine, with revenue up 29% and volumes up 17%; large-panel volumes grew more than 25%. Management cited new products, higher-value testing, payer wins, customer-interface improvements, and sales-force expansion as drivers of continued growth and further AUP upside.
• RaDaR ST’s reimbursement and adoption footprint is expanding after MolDX coverage for immunotherapy monitoring, with two additional indications under review and a commercial payer expected to cover all MolDX-reimbursed indications starting December 15. Management reported improving monthly volumes and a roughly 30% attachment rate to other NeoGenomics tests, though more meaningful revenue is expected in 2028 and beyond.
• The non-clinical business declined about 10% year over year, pressured by legacy, lower-margin pharma contracts that the company is evaluating or exiting. Near-term profitability also faces potential 2027 PAMA pressure, unreimbursed MRD testing costs, and temporary receivables effects from the XiFin revenue-cycle-management implementation.
• Warren Stone will become CEO on January 4, 2027, while Tony Zook becomes Executive Chair. Management emphasized strategic continuity and plans to provide a broader 2027 outlook, including an investor day, in the first half of next year.

NeoGenomics Stock Performance

NeoGenomics stock opened at $17.99 on Thursday. The firm has a 50-day moving average of $17.64 and a 200-day moving average of $12.77. NeoGenomics has a 1-year low of $7.07 and a 1-year high of $20.15. The firm has a market cap of $2.31 billion, a P/E ratio of -44.97 and a beta of 1.79. The company has a current ratio of 3.60, a quick ratio of 3.35 and a debt-to-equity ratio of 0.48.

Analyst Ratings Changes

NEO has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, October 12th. Zacks Research downgraded shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Craig Hallum restated a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a report on Wednesday, July 29th. BTIG Research reaffirmed a “buy” rating and issued a $28.00 price objective on shares of NeoGenomics in a research note on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of NeoGenomics in a report on Wednesday, October 7th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average price target of $19.57.

Key Stories Impacting NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Third-quarter results exceeded expectations. NeoGenomics reported adjusted earnings of $0.07 per share, ahead of the $0.06 consensus estimate, while revenue reached approximately $209.25 million versus expectations of $206.70 million. Revenue increased 11.3% year over year, and earnings more than doubled from $0.03 per share in the prior-year quarter. NeoGenomics Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised its 2026 revenue guidance. The company now expects full-year revenue of $807 million to $809 million, signaling confidence in continued testing demand and improving operating performance. The raised outlook was highlighted alongside the quarterly earnings beat. NeoGenomics Raises 2026 Guidance
• Positive Sentiment: The earnings outlook improved despite ongoing profitability challenges. The results reinforce the company’s growth trajectory, although NeoGenomics continues to report a negative net margin and negative return on equity. NeoGenomics Earnings Call Transcript

About NeoGenomics

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.